---
title: "3SBIO and Pfizer have entered into a licensing agreement for the PD-1/VEGF bispecific antibody (SSGJ-707)"
description: "3SBIO signed an exclusive licensing agreement with Pfizer, authorizing Pfizer to develop, produce, and commercialize its PD-1/VEGF bispecific antibody SSGJ-707 globally (excluding mainland China). 3SB"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/240914212.md"
published_at: "2025-05-19T23:15:03.000Z"
---

# 3SBIO and Pfizer have entered into a licensing agreement for the PD-1/VEGF bispecific antibody (SSGJ-707)

> 3SBIO signed an exclusive licensing agreement with Pfizer, authorizing Pfizer to develop, produce, and commercialize its PD-1/VEGF bispecific antibody SSGJ-707 globally (excluding mainland China). 3SBIO retains relevant rights in China. The agreement includes a $1.25 billion upfront payment and up to $4.8 billion in potential payments, in addition, 3SBIO will receive a double-digit percentage royalty. SSGJ-707 is currently undergoing multiple clinical studies in China and has received clinical trial approval from the U.S. FDA

According to the announcement from 3SBIO (01530), on May 19, 2025, the company, Shenyang 3SBIO Pharmaceutical Co., Ltd. (Shenyang 3SBIO, a wholly-owned subsidiary of the company), and Pfizer have entered into an exclusive licensing agreement. 3SBIO Guojian Pharmaceutical (Shanghai) Co., Ltd. (3SBIO Guojian, a subsidiary of the company) will also join the agreement as a signing party.

Under the licensing agreement, the company and Shenyang 3SBIO will grant Pfizer an exclusive license to develop, manufacture, commercialize, and otherwise develop its breakthrough PD-1/VEGF bispecific antibody (“licensed product” or “SSGJ-707”) globally (excluding mainland China). The company and Shenyang 3SBIO will retain the rights to develop, manufacture, commercialize, and otherwise develop the licensed product in mainland China. Pfizer will have the option to commercialize the licensed product in China.

Pfizer shall be responsible for all future trial development and regulatory affairs costs for the licensed product in the licensed territories.

According to the licensing agreement, the group will receive an upfront payment of $1.25 billion and may receive potential payments totaling up to $4.8 billion, including development, regulatory approval, and sales milestone payments. All of the above amounts are non-refundable and non-deductible. The group will also receive a double-digit percentage tiered royalty on the net sales of the product in the licensed territories.

The licensed product is a bispecific antibody targeting PD-1/VEGF independently developed by the group based on its proprietary CLF2 platform. It is currently undergoing multiple clinical studies in China, including a planned Phase III clinical study for first-line treatment of PD-L1 positive locally advanced or metastatic non-small cell lung cancer (NSCLC), which has received breakthrough therapy designation from the National Medical Products Administration (NMPA) in China. Additionally, SSGJ-707 injection is undergoing multiple Phase II studies in China, including first-line treatment of advanced NSCLC, metastatic colorectal cancer, and advanced gynecological tumors in combination with chemotherapy. It has also received approval from the U.S. Food and Drug Administration for its new drug clinical trial application.

Furthermore, Pfizer will subscribe for $100 million worth of common stock of the company at the 30-day volume-weighted average price (subject to applicable rules and regulations, including listing rules) according to the terms set forth in the share subscription agreement (formal agreement) on the effective date. The agreement will be further negotiated and agreed upon by the parties after the date of the licensing agreement. The exact terms and number of new shares to be issued to Pfizer (or its nominees) will be determined and finalized in the formal agreement

### Related Stocks

- [PFE.US - Pfizer](https://longbridge.com/en/quote/PFE.US.md)
- [01530.HK - 3SBIO](https://longbridge.com/en/quote/01530.HK.md)
- [688336.CN - Sunshine Guojian Pharmaceutical](https://longbridge.com/en/quote/688336.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| SpaceX 向上市冲刺：拟 IPO 用双重股权结构，与 xAI 合并后考虑重组债务 | 报道称，双重股权结构将赋予特定股东额外投票权，使马斯克即便持有少数股权，也能保持对公司的绝对控制；马斯克合作的银团在商讨一项融资方案，旨在重组 SpaceX 与 xAI 合并产生的债务，马斯克通过收购 X 并创立 xAI 积累了近 180  | [Link](https://longbridge.com/en/news/275938108.md) |
| OPEC 月报：1 月全球产油盟国产量大幅下滑，维持今明两年需求预测不变 | 受哈萨克斯坦、委内瑞拉及伊朗供应中断影响，OPEC+ 1 月日均产量环比锐减 43.9 万桶至 4244.8 万桶，远超市场预期。其中哈萨克斯坦因 Tengiz 油田停产贡献了过半降幅，但目前该油田已开始复产，供应冲击或为短期。尽管产量骤降 | [Link](https://longbridge.com/en/news/275613183.md) |
| 达利欧万字长文：旧秩序已死，世界重回 “丛林法则”，贸易战和资本战将成常态 | 达利欧宣告世界进入 “大周期” 第六阶段：1945 年后的世界秩序已瓦解，强权即公理，大国冲突将回归原始权力博弈，贸易战、技术战、资本战将常态化并可能升级为军事冲突。慕尼黑安全会议共识印证这一判断：旧秩序已不复存在，欧洲安全架构失效。达利欧 | [Link](https://longbridge.com/en/news/276003775.md) |
| 当 AI 进入医院，“手术失误、错认器官” 等风险也随之而来 | 据美国数据，强生旗下 TruDi 系统引入 AI 后故障报告激增十倍，甚至出现 “导航误导” 致死风险；数据显示，AI 设备获批后首年召回率高达 43%，远超传统设备。然而，美国药监局 FDA 关键团队减员严重，传统监管框架在海量申请前几近 | [Link](https://longbridge.com/en/news/275537054.md) |
| Ultragenyx 制药｜8-K：2025 财年营收 6.73 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/275809108.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.